Core Scientific (CORZ) Projected to Post Quarterly Earnings on Wednesday

Key Points

• Core Scientific is set to announce its Q2 2025 earnings on August 6th, with analysts expecting a loss of ($0.08) per share and revenues of $82.09 million.
• In a recent quarterly report, Core Scientific reported a loss of ($0.10) per share, which was better than analyst expectations, but its revenue fell 55.6% year-over-year to $79.53 million.
• Several analysts have issued varying ratings for Core Scientific, with consensus suggesting a "Hold" rating and a price target of $18.32.

Core Scientific (NASDAQ:CORZ - Get Free Report) is expected to be announcing its Q2 2025 earnings results before the market opens on Wednesday, August 6th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $82.09 million for the quarter.

Core Scientific (NASDAQ:CORZ - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.02. The firm had revenue of $79.53 million during the quarter, compared to analyst estimates of $92.04 million. Core Scientific's revenue for the quarter was down 55.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.78 EPS.

Core Scientific Stock Performance

Shares of CORZ stock traded down $0.89 during trading on Friday, hitting $12.65. The company had a trading volume of 14,607,142 shares, compared to its average volume of 16,365,378. The firm has a market capitalization of $3.77 billion, a P/E ratio of -2.51 and a beta of 6.71. The stock's 50-day moving average price is $13.19 and its 200 day moving average price is $11.05. Core Scientific has a one year low of $6.20 and a one year high of $18.63.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Citizens Jmp cut Core Scientific from a "strong-buy" rating to a "hold" rating in a research note on Monday, July 14th. Citigroup cut Core Scientific from an "outperform" rating to a "market perform" rating in a research note on Monday, July 14th. Needham & Company LLC cut Core Scientific from a "moderate buy" rating to a "hold" rating and set a $18.00 target price for the company. in a research note on Thursday, July 10th. Canaccord Genuity Group restated a "buy" rating and set a $17.00 target price on shares of Core Scientific in a research note on Friday, June 27th. Finally, Roth Mkm restated a "buy" rating and set a $20.00 target price on shares of Core Scientific in a research note on Thursday, June 26th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Core Scientific has a consensus rating of "Hold" and a consensus target price of $18.32.

Insiders Place Their Bets

In related news, Director Yadin Rozov acquired 110,000 shares of the firm's stock in a transaction that occurred on Wednesday, May 28th. The stock was acquired at an average cost of $10.87 per share, for a total transaction of $1,195,700.00. Following the completion of the acquisition, the director directly owned 475,687 shares of the company's stock, valued at approximately $5,170,717.69. This trade represents a 30.08% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Todd M. Duchene sold 7,759 shares of the stock in a transaction dated Wednesday, June 25th. The stock was sold at an average price of $12.39, for a total value of $96,134.01. Following the sale, the insider owned 2,049,689 shares of the company's stock, valued at approximately $25,395,646.71. The trade was a 0.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 117,759 shares of company stock valued at $1,391,434 over the last 90 days. 1.40% of the stock is currently owned by company insiders.

Institutional Trading of Core Scientific

A hedge fund recently raised its stake in Core Scientific stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Core Scientific, Inc. (NASDAQ:CORZ - Free Report) by 180.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,109,387 shares of the company's stock after purchasing an additional 714,388 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned about 0.37% of Core Scientific worth $8,032,000 at the end of the most recent reporting period.

About Core Scientific

Core Scientific, Inc provides digital asset mining services in North America. It operates through two segments, Mining and Hosting. The company offers blockchain infrastructure, software solutions, and services; and operates data center mining facilities. It also mines digital assets for its own account; and provides hosting services for other large bitcoin miners, which include deployment, monitoring, trouble shooting, optimization, and maintenance of its customers' digital asset mining equipment.